Literature DB >> 8597143

Modifying toxicokinetics with antidotes.

F J Baud1, S W Borron, C Bismuth.   

Abstract

Five approaches may be described through which antidotes can modify toxicokinetics: (1) Decreased bioavailability of the toxins; (2) Cellular redistribution of the toxin in the organism; (3) Promotion of elimination in an unchanged form; (4) Slowing of metabolic activation pathways; (5) Acceleration of metabolic deactivation pathways. However, the ability to modify toxicokinetics with a new treatment, while demonstrating an understanding of the mechanism of action, must never be construed to be, in and of itself, the goal of therapy. The ultimate evaluation of an antidote modifying toxicokinetics is strictly clinical.

Mesh:

Substances:

Year:  1995        PMID: 8597143     DOI: 10.1016/0378-4274(95)03520-6

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  3 in total

Review 1.  Advances in the management of digoxin toxicity in the older patient.

Authors:  S W Borron; C Bismuth; J Muszynski
Journal:  Drugs Aging       Date:  1997-01       Impact factor: 3.923

Review 2.  Pharmacokinetic considerations in clinical toxicology: clinical applications.

Authors:  Darren M Roberts; Nick A Buckley
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Cloning and characterization of a hybridoma secreting a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-specific monoclonal antibody and recombinant F(ab).

Authors:  Heather Wanczyk; Tolga Barker; Debra Rood; Daniel I Zapata; Amy R Howell; Stewart K Richardson; John Zinckgraf; Gregory P Marusov; Michael A Lynes; Lawrence K Silbart
Journal:  Toxins (Basel)       Date:  2013-03-19       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.